Drug Profile
Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma
Alternative Names: DA-3113; DMB-3113Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical; Meiji Seika Pharma
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Japan (SC, Injection)
- 19 Jul 2021 Adalimumab biosimilar is still in phase-I trials for Rheumatoid-arthritis (In volunteers) in Japan (Dong-A Socio Holdings pipeline, July 2021)
- 19 Jul 2021 Adalimumab biosimilar - Dong-A ST/Meiji Seika Pharma is available for licensing in (excluding Japan, South Korea) as of 19 Jul 2021. http://en.donga.co.kr/Pass.da?viewPath=/b03/bioMedicine#